Laurus Labs Limited (LAURUSLABS) — Corporate Action | 25 July 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
NCLT approved Laurus Labs' demerger and amalgamation scheme.
🔄 What Changed
NCLT set September 10, 2026 as next hearing date for scheme approval.
🔮 What's Next
Next hearing scheduled for September 10, 2026.
💡 Investor Takeaway
The restructuring may unlock value by separating businesses.

Laurus Labs announced that the National Company Law Tribunal approved its scheme to demerge Laurus Synthesis Private Limited and amalgamate its remaining business, directing next hearing on September 10, 2026.

📄 View Original Announcement (PDF)

About Laurus Labs Limited (LAURUSLABS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹1,03,025.6 Cr P/E: 94.1 ROE: 20.6% ROCE: 20.8% Div Yield: 0.06%

View full LAURUSLABS stock details →

📡 Get AI alerts when LAURUSLABS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LAURUSLABS — Free

📊 More LAURUSLABS filings

See all LAURUSLABS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LAURUSLABS files new disclosures

Track LAURUSLABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LAURUSLABS — Free

Free account · 2 AI queries/day